Abstract Number: 2023 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Background/Purpose: Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, was efficacious and well tolerated vs placebo (PBO) during the first 14 weeks (wks) of the phase…Abstract Number: 0886 • ACR Convergence 2020
Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) response criteria and AS Disease Activity Score (ASDAS) are both commonly used, rigorous composite indices consisting of components…Abstract Number: 1372 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement
Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy for the treatment of AS in patients (pts) who were NSAID inadequate responders (IR).1 Pts with psoriatic arthritis (PsA)…Abstract Number: 2024 • ACR Convergence 2020
Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial
Background/Purpose: The oral, selective Janus kinase 1 inhibitor filgotinib (FIL) significantly improved Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation scores (bone marrow edema) in…Abstract Number: 0896 • ACR Convergence 2020
Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs
Background/Purpose: Pain is a dominant symptom of psoriatic arthritis (PsA), and pain reduction is a priority for patients (pts) that is often assessed in clinical…Abstract Number: 1441 • ACR Convergence 2020
Effects of Belimumab on Renal Outcomes, Overall SLE Control and Biomarkers: Findings from a Phase 3, Randomized, Placebo-controlled 104-week Study in Patients with Active Lupus Nephritis
Background/Purpose: Belimumab (BEL) has demonstrated efficacy in systemic lupus erythematosus (SLE) in 4 positive pivotal trials. This study assessed the efficacy and safety of intravenous…Abstract Number: 0897 • ACR Convergence 2020
Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept
Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…Abstract Number: 1444 • ACR Convergence 2020
Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial
Background/Purpose: Recommendations for axial spondyloarthritis (axSpA) management include tight control and treat-to-target (TC), but no study has evaluated its potential benefit. The objective of this…Abstract Number: 0907 • ACR Convergence 2020
Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)
Background/Purpose: EQUATOR (NCT03101670) was a randomized, 16-week, Phase 2, multicenter, double-blind, placebo (PBO)‑controlled trial of filgotinib (FIL) in patients with active PsA ( Mease P,…Abstract Number: 1467 • ACR Convergence 2020
Effectiveness of the Making It Work™ Program at Improving Presenteeism and Work Cessation in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial
Background/Purpose: Arthritis often leads to presenteeism (decreased at-work productivity) and permanent work disability, the worst occupational outcome of a disease, leading to reduced quality of…Abstract Number: 0910 • ACR Convergence 2020
Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2
Background/Purpose: EQUATOR (NCT03101670) was a 16-week, Phase 2, double-blind, randomized placebo-controlled trial of filgotinib for PsA. At Week 16, placebo-treated patients could switch to filgotinib…Abstract Number: 1483 • ACR Convergence 2020
A Randomised Controlled Trial Evaluating the Efficacy of Internet-based Exercises Aimed at Treating Knee Osteoarthritis (iBEAT-OA)
Background/Purpose: Osteoarthritis (OA) is the commonest cause of pain and disability in the general population and is usually managed by family doctors and physiotherapists. This…Abstract Number: 0935 • ACR Convergence 2020
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Trial of BIIB059, an Anti-Blood Dendritic Cell Antigen 2 Antibody, in SLE
Background/Purpose: Type I interferons (IFN-I), inflammatory mediators principally produced by plasmacytoid dendritic cells (pDCs), components of the innate immune system, have been implicated in the…Abstract Number: 1484 • ACR Convergence 2020
Efficacy of Tocilizumab in Patients with Hand Osteoarthritis: Double Blind, Randomized, Placebo Controlled, Multicenter Trial
Background/Purpose: To evaluate the efficacy of tocilizumab, an antibody against interleukin-6 receptor (IL-6R), in patients with hand osteoarthritis.Methods: This was a multicenter, 12-week, randomized, double-blind,…Abstract Number: 0955 • ACR Convergence 2020
Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rash and progressive proximal muscle weakness. Intravenous immunoglobulin (IVIg) has long been…